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Simple Summary: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer treatment
landscape, yet the impact of the timing of the use of an immunosuppressive agent such as steroids
on ICI outcomes is poorly described. Utilizing the SEER-Medicare-linked dataset, this study explored the relationship between timing of steroid exposure preceding ICI administration and subsequent treatment outcomes in melanoma. We found steroid use up to 3 months prior increased
risk for mortality up to 6 months after ICI initiation. Furthermore, steroid use was a significant
contributor to poorer outcomes from ICIs, which should be considered before prescribing ICIs.
Abstract: Immune checkpoint inhibitors (ICIs) harness the immune system and are the therapy of
choice for multiple cancers. Although immunosuppressive agents such as steroids are also used in
many cancers, it is unknown how their timing affects treatment outcomes. Thus, we investigated
the relationship between the timing of steroid exposure preceding ICI administration and subsequent treatment outcomes in melanoma. This population-based study utilized the SEER-Medicarelinked database to identify patients diagnosed with melanoma between 1991 and 2015 and receiving
ICIs between 2010 and 2016, examining last steroid exposure in the 12 months preceding ICI. The
main outcome was all-cause mortality (ACM) after ICIs. Modifications of the Cox proportional hazards model were used to calculate time-dependent hazards. Of 1671 patients with melanoma receiving ICIs, 907 received steroids. Compared with no steroids, last steroid exposures ≤1 month and
1–3 months prior to ICIs were associated with a 126% and 51% higher ACM within 3 months post
ICI initiation, respectively (hazard ratio (HR): 2.26, 95% CI: 1.65–3.08; and HR: 1.51, 95% CI: 1.01–
2.27). Steroid exposure within 3 months of initiating ICIs was associated with increased mortality
up to 6 months after ICI. Further investigation is warranted to elucidate mechanisms affecting outcomes due to steroids.
Keywords: immunotherapy; steroids; melanoma; overall mortality; all-cause mortality;
hospitalizations; immune checkpoint inhibitors

ativecommons.org/licenses/by/4.0/).
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1. Introduction
According to the National Cancer Institute, approximately 40% of individuals in the
United States (US) will be diagnosed with cancer in their lifetime [1]. Since first being
approved in 2011 by the US Food and Drug Administration, immune checkpoint inhibitors (ICIs) such as ipilimumab (cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor), pembrolizumab, and nivolumab (programmed cell death protein (PD-1) inhibitors) have played a significant role in survival after cancer diagnosis. ICIs, which harness
the immune system and amplify its natural ability to fight cancer, have produced improved outcomes and increased survival rates, thereby becoming a major pillar of cancer
therapy. Providing significant improvements in survival, durable responses, and comparatively fewer adverse events, ICIs are currently used in multiple cancers, such as unresectable hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, colorectal
cancer, etc. [2–5]. In cutaneous melanoma, they are used in Stage III/IV resectable disease
as adjuvant therapy, in Stage IV unresectable melanoma as primary therapy, and in recurrent disease [6–9].
Melanoma was the first site to be approved for ICIs; since then, ICIs have measurably
improved the prognosis of metastatic melanoma by reversing effector T-cell dysfunction,
thereby strengthening anti-tumor immune response [10,11]. A recent update of the PhaseIII CheckMate 067 trial for melanoma found that ipilimumab and nivolumab combination
has the highest five-year survival for melanoma (52%) compared to nivolumab alone
(44%) and ipilimumab alone (26%) [3]. Despite the efficacy of ICIs, this improvement in
survival is limited only to 30–40% of patients [10,12,13]; hence, it is important to identify
factors that drive ICI response to optimize treatment strategies.
One in five metastatic melanoma patients has brain metastasis at the time of diagnosis, and three of four patients develop it over time. Traditionally, these are treated with
systemic steroids. Steroid use impairs the immune system at various levels, from inhibition of acute inflammation to immunomodulatory effects [14]. This raises a major concern
since ICIs require a robust immune response. Moreover, steroids are widely used in cancer patients and are known to have a far-reaching impact, ranging from curative treatment
in certain cancers such as leukemia and lymphoma to supportive therapy in brain metastases [15–20].
Most clinical trials of ICIs have excluded patients treated with immunosuppressive
agents (such as prednisone ≥10 mg) that can impair T-cell functions [21–24]. Therefore,
data are limited on the outcomes for patients not eligible for ICI trials and receiving ICI in
the real world. Several institution-based studies, primarily in advanced/metastatic nonsmall cell lung cancer (NSCLC), have shown worsened clinical outcomes with steroid exposure at baseline [25] or after initiation of ICI [26], including decreased overall response
rate, shorter progression-free survival, and lower overall survival. It has also been reported that the use of steroids for immune-related adverse events concurrently with ICIs
does not impact survival among patients [5]. Therefore, the impact of steroid use on the
effectiveness of ICIs is debatable.
Specifically, the relationship between the timing of steroid exposure prior to ICI initiation and subsequent outcomes for patients with melanoma remains unknown. It is also
unclear how long the effects of steroids may last. Thus, we conducted a population-based
study to fill these knowledge gaps by focusing on melanoma patients using steroids prior
to ICI initiation and their treatment outcomes.
2. Materials and Methods
This study was approved by the Institutional Review Board at Thomas Jefferson University IRB 17D.389.
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2.1. Data Source
We utilized the Surveillance, Epidemiology, and End Results linked Medicare (SEERMedicare) database for this study, which includes all patients with cancer aged 65 and
over. As of 2017, the SEER program covers approximately 31% of the US population with
a 98% case ascertainment rate, and it collects data on cancer status at diagnosis, primary
cancer therapy, demographic characteristics, and cause of death among patients with cancer [27]. Medicare is the major health insurance provider among Americans aged 65 years
and over and covers approximately 18% of the entire US population [28]. Part A of Medicare provides coverage for hospital care, skilled nursing facility services, other institutional care, some home health care, and hospice care [29]. Part B covers services from physicians, other health professionals, ambulatory surgical centers, outpatient dialysis, home
health, and other ambulatory services [29]. Part D covers prescription drugs under private
drug plans [29].
2.2. Study Participants
We identified patients diagnosed with melanoma between 1 January 1991 and 31 December 2015 from the patient entitlement and diagnosis summary files. For patients with
multiple diagnoses of melanoma, the most recent melanoma diagnosis was used to identify patients. Patients were excluded if melanoma was diagnosed at death or autopsy. Patients were also excluded if they were enrolled in a health maintenance organization, or
had no Medicare parts A, B, or D coverage during the study period.
2.3. Drug Exposures
The ICIs included in the study were ipilimumab (YERVOY®; identified using the
Healthcare Common Procedure Coding System (HCPCS) code “J9228”), nivolumab
(OPDIVO®; HCPCS code “J9229”), pembrolizumab (KEYTRUDA®; HCPCS code “J9271”),
and ipilimumab/nivolumab combination. The last prescription of all intravenous and injectable steroids prescribed within 12 months prior to ICI initiation were included in the
study. For oral steroids, the last date of steroid exposure was calculated by adding the
information on days of supply to the last prescription date. All inhalational and topical
steroids were excluded from the analysis. In the database, medication follow-up information was available until 31 December 2016 for all patients. Therefore, all drug exposures
were identified from Medicare claims between 1 January 2010 and 31 December 2016.
2.4. Steroid-Exposure Timing
According to the timing of their last steroid exposure during the 12 months prior to
ICI initiation, patients were grouped into one of four categories: (a) ≤1 month prior, (b) 1
month to ≤3 months prior, (c) 3 to 12 months prior, or (d) no steroids (reference group).
2.5. Endpoints
The primary endpoint was all-cause mortality (ACM). The survival time was defined
as the time from the first dose of ICIs until death or the end of the follow-up period. The
secondary endpoint was the risk of inpatient ER and non-ER hospitalization following the
initiation of ICIs. Patients were followed until death or the last follow-up date, 31 December 2016.
2.6. Descriptive Variables
Demographic variables included in the study were age at the time of diagnosis, sex,
race, marital status, income, SEER region, year of diagnosis, and state buy-in. Clinical variables included in the study were cancer stage at the time of diagnosis and CCI.
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2.7. Statistical Analysis
Descriptive statistics were presented for continuous variables as medians with interquartile ranges, and for categorical variables as frequency counts with percentages and
chi-square tests.
2.8. Modeling All-Cause Mortality (ACM)
Median survival was estimated using Kaplan–Meier methods compared by log-rank
test [30]. The crude overall ACM incidence rates were estimated as the number of deaths
divided by the number of patients at risk by steroid-exposure timing groups. Cox modeling was used to examine the association between ACM and the timing of the last steroid
exposure after adjusting for all demographic and clinical variables [31]. The Schoenfeld
residual plots were assessed for time dependence between last steroid-exposure timing
prior to ICI initiation and ACM. We observed time-dependent hazards that violated the
proportional hazards assumption. To address this, we programmed survival time indicator variables to interact with the steroid-timing-exposure indicator variables in the model
to represent the interaction between steroid-exposure timing and follow-up time periods,
allowing the hazards model coefficients to change during survival at 3 months and again
at 6 months after initiating ICI [32].
2.9. Modeling Hospitalizations
We stratified hospitalizations as ER or non-ER because ER hospitalizations are associated with more severe symptoms and higher cost to the patient as well as the health
system [33]. The counting process approach was used for structuring the survival data for
recurrent events as well as for computing the time to hospitalization events for non-ER
and ER hospitalizations, respectively [34]. This method is an extension of the Cox modeling framework, which is useful when an outcome event of interest can recur. The time at
risk for hospitalization for each patient was calculated as the difference between the time
of ICI initiation and the time of death or the end of the follow-up period. These models
were used to estimate hospitalization HRs adjusted for covariates, including age, sex,
Charlson comorbidity index (CCI), marital status, and the year of diagnosis for each patient. The proportional hazards assumption was violated, so we applied the same approach to allow the hospitalization–hazards model coefficients to change during survival
at 3 months and again at 6 months, after initiating ICI as described above for modeling
ACM.
2.10. Pre-Planned Evaluation of Unmeasured Confounding Effects
To assess the robustness of our study results, we used E-values to evaluate the potential effects that unmeasured confounding would need to have in order to change the
conclusions [35]. The E-value measures the minimum strength of association that an unmeasured confounder must have with both the exposure and outcome, while taking into
account all potential covariates, to negate the observed exposure–outcome association by
making the estimated HR equal to 1.
The significance level of all tests was set a priori at the 0.05 level. We performed all
the analyses with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
We identified 1671 eligible patients for this study (858 prescribed ipilimumab, 258
prescribed nivolumab, 456 prescribed pembrolizumab, and 99 prescribed an ipilimumab/nivolumab combination) (Figure 1). Of these, 864 (51.70%) were exposed to steroids within 12 months prior to ICI initiation. Using the sequence variable, we identified
that for 89.7% of the patients, melanoma was either the only cancer diagnosis in the dataset or was the first cancer to be diagnosed. The numbers of patients exposed to steroids
within 1 month, 1 to ≤3 months, and 3 to 12 months prior to ICI initiation were 343, 215,
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and 306, respectively. The demographics and clinical characteristics of patients exposed
and those not exposed to steroids were similar (Table 1). Patients (median age 68) were
predominantly male (71.2%), white (97.3%), married (61.5%), or non-metastatic (M0) at
the time of primary diagnosis (77.3%) (Table 1). The median survival for patients without
steroid exposure was 20.5 months and median survival for patients without steroid exposure was 20.5 months, median survival for those exposed to steroids 4–12 months prior
was 21.2 months, median survival for those exposed 1 to ≤3 months prior was 14.0 months,
and median survival for those exposed ≤1 month prior was 8.9 months (p < 0.05; Table S1).

Figure 1. Consort flow diagram.
Table 1. Demographic and clinical characteristics of the study sample by steroid-exposure status in
the 12 months prior to ICI initiation.

Characteristic
Sex
Male
Female
Race
White
Non-white
Marital status
Missing and unknown

Total
Participants
(N = 1671)

No
Steroids
(N = 807)

Steroids
(N = 864)

1189 (71.2)
482 (28.9)

590 (73.1)
217 (26.9)

599 (69.2)
265 (30.7)

0.088

1626 (97.3)
45 (2.7)

784 (97.2)
23 (2.9)

842 (97.5)
22 (2.5)

0.702

193 (11.6)

86 (10.7)

107 (12.4)

p-Value

0.234
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Single (never married), Unmarried
or domestic partner (same sex or
opposite sex or unregistered)
Widowed, divorced, and
separated
Married (including common law)
Age at diagnosis, median (IQR)
Age at diagnosis
<60
60–69
70–79
80+
Age at first ICI use, median (IQR)
Year of diagnosis
1991–1999
2000–2005
2006–2010
2011–2015
Sequence
Only
1st
Subsequent (2nd–11th)
Charlson comorbidity index
0
1
≥2
SEER region
Northeast
South
North Central
West
State buy in 1
Yes
No
Clinical T stage at diagnosis
T0
T1
T2
T3
T4
TX
Clinical N stage at diagnosis
N0
N1
NX
missing
Clinical M stage at diagnosis
M0
All M1
MX
Missing

196 (11.7)

97 (12.0)

99 (11.5)

254 (15.2)

136 (16.9)

118 (13.7)

1028 (61.5)
69 (63–75)

488 (60.5)
69 (64–76)

540 (62.5)
68 (63–74)

244 (14.6)
648 (38.8)
583 (32.9)
196 (11.7)
75 (70–81)

113 (14.0)
295 (36.6)
283 (35.1)
116 (14.4)
75 (70–81)

131 (15.2)
353 (40.9)
300 (34.7)
80 (9.3)
74 (69–80)

107 (6.4)
278 (16.6)
470 (28.1)
816 (48.8)

46 (6.0)
129 (16.9)
204 (26.7)
385 (50.4)

61 (6.7)
149 (16.4)
266 (29.3)
431 (47.5)

807 (48.3)
691 (41.4)
173 (10.4)

411 (50.9)
313 (38.8)
83 (10.3)

396 (45.8)
378 (43.8)
90 (10.4)

973 (58.2)
336 (20.1)
360 (21.5)

495 (61.4)
152 (18.9)
159 (19.7)

478 (55.4)
184 (21.3)
201 (23.2)

386 (23.1)
344 (20.6)
132 (7.9)
809 (49.4)

196 (24.3)
150 (18.6)
69 (8.6)
392 (48.6)

190 (21.6)
194 (22.5)
63 (7.3)
417 (48.3)

255(15.2)
1416 (84.7)

136 (16.9)
671 (83.2)

119 (13.8)
745 (86.2)

91 (5.5)
322 (19.3)
178 (10.7)
70 (4.2)
706 (42.3)
284 (17.0)

32 (4.0)
165 (20.5)
79 (9.8)
36 (4.5)
362 (44.9)
128 (15.9)

59 (6.8)
157 (18.2)
99 (11.5)
34 (3.9)
344 (49.1)
156 (18.1)

964 (57.7)
210 (12.6)
119 (7.12)
377 (22.6)

459 (55.9)
109 (13.5)
59 (7.3)
180 (22.3)

505 (58.5)
101 (11.7)
60 (6.9)
197 (22.8)

1292 (77.3)
153 (0.1)
194 (11.6)
32 (1.9)

631 (78.2)
65 (0.1)
91 (11.3)
20 (2.5)

661 (76.5)
88 (0.1)
103 (11.9)
12 (1.4)

0.009

0.554

0.094

0.043

0.185

0.080

0.01

0.675

0.432
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Melanoma specific mortality as of
31 December 2016
Dead
Alive
All-cause mortality as of 31
December 2016
Dead
Alive

398 (23.8)
1273 (76.2)

189 (22.4)
618 (76.6)

209 (24.2)
655 (75.8)

1031 (61.7)
640 (38.3)

482 (59.7)
325 (40.3)

549 (63.5)
315 (36.5)

0.712

0.011

State buy-in: indicating that the state pays part or all of the patient’s Medicare Part B premium or
that the person is in the Medicaid program, bolt values represent significant values.
1

3.1. ACM and Steroid Exposure Prior to ICI Initiation
Figure 2 and Table 2 depict the results from the time-dependent hazards model for
ACM, evaluating its association with steroids prior to ICIs. Exposures to steroids ≤1
month and 1 to ≤3 months prior to ICI initiation were associated with a 126% and 51%
higher ACM within 3 months post ICI initiation, respectively (HR = 2.26; 95% CI: 1.65–
3.08; p < 0.001 for 1 month prior and HR = 1.51; 95% CI: 1.01–2.27; p = 0.04 for 1 to ≤3 months
prior). Similarly, steroid exposure ≤1 month prior to ICI initiation was associated with a
100% increase in ACM 3 to 6 months after ICI initiation (HR = 2.00; 95%CI: 1.42–2.82; p <
0.001). In general, the nearer the last steroid exposure to ICI initiation, the higher the ACM
risk. This association followed an approximately linear trend with a statistically significant non-zero slope (p < 0.001).
Table 2. Steroid-exposure timing prior to ICI initiation and its time-dependent association with allcause mortality after ICI initiation.

Timing of Steroid
Exposure Prior to ICI
Initiation

0 to ≤3 Months 3 to ≤6 Months Post ≥6 Months Post ICI
Post ICI Initiation
ICI Initiation
Initiation
Hazard Ratios 1
Hazard Ratios
Hazard Ratios
(95% CI)
(95% CI)
(95% CI)

No steroids in 12 months
Ref
before ICI
Steroids ≤ 1 month prior
2.26 (1.65–3.08) 2
to ICI
Steroids 1 to ≤3 months
1.51 (1.01–2.27) 2
prior to ICI
Steroids 3 to 12 months
1.02 (0.68–1.52)
prior to ICI

Ref

Ref

2.00 (1.42–2.82) 2

1.05 (0.82–1.35)

1.04 (0.65–1.35)

0.91 (0.68–1.22)

1.25 (0.86–1.84)

0.98 (0.77–1.24)

Hazard ratios estimated by time-dependent hazards model adjusted for sex, age, marital status,
sequence of cancer diagnosis, year of diagnosis, and Charlson comorbidity index. 2 p < 0.001.
1.
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Figure 2. Time-dependent all-cause mortality hazard ratios for all steroid-exposure groups and survival time periods.

3.2. ER-Hospitalization Risk and Timing of Steroid Exposure before ICI initiation
Steroid exposure within 12 months of ICI initiation was also associated with a higher
incidence of ER hospitalizations. Figure 3 panel A and Table 3 show the HRs and 95% CI
for ER hospitalizations post ICI initiation for different steroid-exposure timing groups.
Steroids within 1 month prior to ICI initiation was associated with a 62% higher incidence
of ER hospitalizations during the first 3 months (HR = 1.62; 95% CI: 1.36–1.94; p < 0.001)
and a 37% higher incidence of ER hospitalizations during the next 3 months of survival
post ICI initiation (HR: 1.36; 95% CI: 1.08–1.74; p = 0.01). Steroid exposure within 1 to ≤3
months prior was associated with a 27% higher incidence of ER hospitalization during the
first 3 months post initiation (HR: 1.27; 95% CI: 1.01–1.58; p = 0.037). Similarly, steroid
exposure 3 to 12 months prior was associated with higher HR for ER hospitalizations 3
months post ICI initiation compared to patients with no prior steroids (Table 3). Beyond
the first six months post ICI initiation, steroid exposure was not associated with an increase in ER hospitalizations.
Table 3. Steroid-exposure timing prior to ICI initiation and its time-dependent association with ER
hospitalization after ICI initiation.

0 to ≤3 Months Post ICI
Initiation
Hazard Ratios 1
(95% CI)
No steroids in 12 months before ICI
Ref
Steroids ≤1 month prior to ICI
1.62 (1.36–1.94) 2
Steroids 1 to ≤3 months prior to ICI
1.27 (1.01–1.58) 2
Steroids 3 to 12 months prior to ICI
1.15 (0.94–1.41)

Timing of Steroid Exposure Prior to
ICI Initiation

3 to ≤6 Months Post ICI
Initiation
Hazard Ratios 1
(95% CI)
Ref
1.37 (1.08–1.74) 2
1.16 (0.88–1.54)
1.11 (0.87–1.42)

≥6 Months Post ICI
Initiation
Hazard Ratios 1
(95% CI)
Ref
1.01 (0.83–1.24)
0.94 (0.75–1.17)
0.84 (0.70–1.03)

Hazard ratios estimated by time-dependent hazards model adjusted for sex, age, marital status,
sequence of cancer diagnosis, year of diagnosis, and Charlson comorbidity index. 2 p < 0.001.
1
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(a)

(b)

Figure 3. Time-dependent ER (panel a) and non-ER hospitalization (panel b) hazard ratios for all
steroid-exposure groups and survival time periods. (a) Steroid exposure prior to ICI use is associated with higher ER hospitalization rates up to 6 months post ICI initiation. Steroid exposure up to
3 months prior is associated with higher ER hospitalization rates up to 6 months post ICI initiation.
The elevated risk of ER hospitalization associated with prior steroid exposure diminished over time
and vanished by 6 months post ICI. (b) For non-ER hospitalizations, steroid exposure 1 month prior
is associated with higher non-ER hospitalizations up to 3 months post ICI initiation and steroid
exposure 1–3 months prior is associated with higher non-ER hospitalization rates up to 6 months
post ICI initiation. The elevated risk of non-ER hospitalization associated with prior steroid exposure diminished over time and vanished by 6 months post ICI.

3.3. Non-ER-Hospitalization Risk and Steroid Exposure before ICI Initiation
Figure 3 panel B and Table S2 show the HRs and 95% CI for non-ER hospitalizations
post ICI initiation for different steroid-exposure timing groups. For the first 3 months of
survival post ICI-initiation, steroid exposure within ≤1 month prior was associated with
a 77% higher risk of non-ER hospitalizations (HR = 1.77; 95% CI: 1.29–2.45; p = 0.005).
3.4. Pre-Planned Analysis to Evaluate Unmeasured Confounding
The E-values in Table 4 suggest the minimum strength of unmeasured confounding
association that would nullify the HRs to which they specifically correspond in Figure 2.
It is unlikely that an unmeasured or unknown confounder would change our HR results
for ACM during the first 6 months of survival after ICI initiation associated with steroid
exposure within 1 month prior to ICI initiation. The confounder would need to have a
relative risk association of at least 3.27 with both ACM and exposure to steroids within 1
month prior to ICI initiation. It would need to have relative risk associations greater than
3.44 for both ACM and steroid exposure 1 month prior.
Table 4. Assessment of the robustness (using E-values 1) of observed associations for all-cause mortality with steroid exposure presented in Figure 2.

Timing of Steroid
0 to ≤3 Months 3 to ≤6 Months Post ≥6 Months Post ICI
Exposure Prior to ICI
Post ICI Initiation
ICI Initiation
initiation
Initiation
Hazard Ratios
Hazard Ratios
Hazard Ratios 1
Steroids ≤ 1 month prior to
3.27
3.44
1.58
ICI
Steroids 1 to ≤ 3 months
2.82
1.77
1.49
prior to ICI
Steroids 3 to 12 months
1.89
1.69
1.40
prior to ICI
E-value measures the minimum strength of association that an unmeasured confounder must
have with both the exposure and outcome, and considers the covariates to nullify the observed
1.
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exposure–outcome association. The further an E-value shown here is from 1, the less likely that
unmeasured confounding would account for its corresponding HR in Figure 2.

4. Discussion
This is the first population-based study to demonstrate a strong association between
the timing of steroids preceding ICI initiation and clinical outcomes among patients with
melanoma. We found that shorter time between last steroid exposure and ICI initiation
was associated with significantly worse outcomes. Specifically, steroid exposure within 3
months of initiating ICIs was associated with increased mortality during the first 6 months
after ICI initiation, with risk elevated at least twofold if steroids were used within 1 month
prior to initiation. Additionally, these patients were more likely to have ER and non-ER
hospitalizations when exposed to steroids within 1 month prior to ICI initiation. These
findings are thought-provoking given the concerns for the potential ICI-suppressive effects of steroids. Our data suggest potential interplay between ICIs and immunosuppressive agents; therefore, oncologists and cancer caregivers are advised to take into account
the potential effects of immunosuppressive agents such as steroids before initiating ICIs.
Our findings are consistent with another retrospective study that found that baseline
steroid exposure within 30 days of receiving ICIs for NSCLC was associated with worse
ACM after adjusting for covariates, including history of brain metastases [25]. Another
study using the large Flatiron dataset found that baseline steroid exposure was associated
with worse ACM among patients with NSCLC and melanoma [36]. We found a similar
trend in our study; patients with prior steroid exposure had worse ACM compared to
those without steroid exposure. Moreover, we suspect that the ACM in our study population could be higher compared to results from clinical trials, since clinical trials usually
exclude patients with active, untreated metastases, and those with high baseline or
chronic steroid exposure. In our study, patients exposed to steroids within 1 month before
ICI initiation did much worse than the expected mortality; median OS was 8.9 months for
patients with steroids exposure within 1 month prior to ICI compared to 11.4 months in a
meta-analysis of over 1600 patients [20]. We posit that the increase in short-term ACM is
suggestive of an acute medical process. However, the exact mechanism is unknown and
further studies are needed.
Exposure to steroids prior to ICI initiation was associated with higher risk of ER hospitalizations post ICI. Due to data limitations, we were unable to address whether the
increased hospitalizations were a result of immune-related adverse events or steroid exposure. To minimize unmeasured confounding effects, we chose to model risk of hospitalization (6 months post ICI vs. 6 months before ICI) because socioeconomic status, access
to care, health habits, and comorbidities were likely to have modest changes within a short
period of time. In addition, we used E-values to assess the robustness of the findings and
found that any unmeasured confounding would require a high HR to nullify the major
conclusions of the study.
Melanoma was the first cancer approved for ICIs and thus has the most mature data
for analyzing steroids preceding ICI initiation. Unlike NSCLC, where COPD and brain
metastases are more likely to require steroids [37], the indications for steroids preceding
ICIs in our population is unclear, since the SEER-Medicare database does not reliably capture metastasis information beyond initial cancer diagnosis. However, having at least one
comorbidity increased the likelihood of steroid exposure, which could signal poorer
health overall. Although patients with CCI ≥ 2 had higher mortality risk and hospitalization risks in all cohorts, steroid exposure remained an independently prognostic factor
after adjusting for comorbidity and relevant covariates. Thus, our findings are robust
among melanoma patients with steroid exposure.
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4.1. Potential Mechanisms
One potential explanation for these results is the role played by T cells in the mechanism of action for steroids and ICIs. Steroid exposure is associated with suppression of Tcell activity, leading to impaired immune function and inferior outcomes [38], whereas
ICIs require the activation of T cells for antitumor activity. Therefore, steroid exposure
prior to ICIs may result in decreasing the efficacy of ICIs due to suppression of the CD8positive T cells that are required for an ICI blockade [24]. A preclinical study found that
dexamethasone increased PD-1 expression in certain subsets of T cells, therefore suggesting that inhibition of PD-1 might overcome T-cell exhaustion [39]. Another study found
that dexamethasone use blocked the proliferation of T cells and attenuated the stimulation
of CD28 cells more than memory T cells. A mouse model further found that although
CTLA-4 inhibition partially restored tumor infiltration of T cells alongside consequent
dexamethasone exposure, there was no significant increase in CD8 T cells, hence suggesting that early exposure to steroids led to significantly suppressed ICI response. Given
these findings, we propose that patients using steroids at baseline should be included in
future clinical trials and data analysis in order to optimize results. To this effect, the NCI
is currently working with multiple cancer sites to conduct two randomized clinical trials
among patients with autoimmune diseases (most using steroids) and cancer receiving
nivolumab: NCT03656627 (Nivolumab in Treating Patients with Autoimmune Disorders
or Advanced, Metastatic, or Unresectable Cancer) and NCT03816345 (A Phase Ib Study of
Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIMNIVO)) [40,41]. Until further information regarding the safety of such concurrent medication use is available, ICIs must be administered with caution and after careful assessment
of the risk–benefit ratio for each patient.
4.2. Strengths and Limitations
The study has several strengths. First, derived from a large, population-based database with broad representation, our study offers excellent real-world generalizability. Second, this is the first study to address the timing effects associated with steroid exposure
within 12 months prior to ICI initiation. Previous studies have not examined the timing
effects beyond 3 months prior. Third, this is the first study using national-level data specific to Medicare patients receiving ICIs. Fourth, this is the first study to include differences in hospitalization risks stratified by ER and non-ER hospitalization among patients
exposed to steroids prior to receiving ICIs. Since ER hospitalizations are associated with
higher cost to the patients as well as the health system, it is important to understand the
difference between the association of steroid exposure and ICIs for both ER and non-ER
hospitalizations.
The study also has limitations. First, given the retrospective nature of the study, we
were unable to formulate a cause–effect relationship between the timing of steroid exposure and the clinical outcomes. Second, the SEER dataset does not provide information
about cancer staging beyond the date of diagnosis; however, based on the treatment dates
in our cohort, we assume that all patients receiving ICIs during the study period had advanced-stage disease since ICIs were only approved for advanced stage disease during
this time window. Third, we did not have any data on laboratory values such as PD-1
status, neutrophil count, neutrophil-to-lymphocyte ratio, tumor mutation burden, or line
of therapy, which limited our analysis. Fourth, due to the limitation of the dataset, we
were unable to identify the dosage of steroids. Fifth, we defined steroid exposure using
only prescription data, not whether or for how long the steroids were actually used. Thus,
there may be some misclassification of steroid exposure. Further studies are warranted to
confirm the relationship between steroid exposure and clinical outcomes of ICIs. These
studies should focus on the dosing of steroids, the type of steroid used, and the difference
between acute and chronic steroid exposure.
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5. Conclusions
The nearer the last steroid exposure to ICI initiation, the higher the ACM risk; thus,
care providers are advised to take this into account and consider the risk–benefit ratio
when making therapeutic decisions. It is recommended that the care team consider delaying steroid exposure and focus on steroid-sparing strategies before initiating ICIs or consider delaying initiating ICIs for 3 months to allow for steroid washout.
Supplementary Materials: The following are available online at www.mdpi.com/article/10.3390/cancers14051296/s1, Table S1: Median survival and cumulative incidence of all-cause
mortality 6 months post ICI initiation, Table S2: Timing of steroid exposure prior to ICI initiation
and its time-dependent association with non-ER hospitalization.
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